Viviana Figueroa Diaz, MD
Transplant Hepatology · New York, NYNPI 1245464361
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,205 of the $4,919 with a category attached, or 65.2%. 11 manufacturers reported payments, led by Gilead at 49.4% of the total. 2025 is the largest year on record at $2,539, 6.0 times the $425 reported in 2019.
Across 46 payments — averaging $106.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Eisai Inc.$2K
- Mirum Pharmaceuticals, Inc.$256
- Ipsen Biopharmaceuticals, Inc$201
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$172
- Intercept Pharmaceuticals, Inc.$93
- plus $191 from 5 others
Across 69 payments — averaging $2812.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$147K
- Eiger Biopharmaceuticals, Inc.$47K
What the payments were for
- Consulting fees$3,20565%
- Food & beverage$1,71435%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 17 | $2,431 |
| Eisai Inc. | 1 | $1,575 |
| Mirum Pharmaceuticals, Inc. | 2 | $256 |
| Ipsen Biopharmaceuticals, Inc | 6 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $172 |
| Intercept Pharmaceuticals, Inc. | 4 | $93 |
| Orphalan Inc | 2 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| AbbVie | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,919 in reported general payments places this provider in the 60th percentile of 36 transplant hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 40 | $57,807 |
| Entecavir | 39 | $10,591 |
| Ursodiol | 66 | $8,092 |
| Tenofovir Disoproxil Fumarate | 14 | $3,383 |
| Lactulose | 14 | $705 |
| Spironolactone | 26 | $218 |
| Ciprofloxacin Hcl | 11 | $114 |
| Carvedilol | 26 | $113 |
| Furosemide | 22 | $92 |
| Prednisone | 15 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $2,431 | $57,80740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 36 transplant hepatology providers in New York.
Other transplant hepatology in New York
- Nikolaos PyrsopoulosNew York$251K
- James ParkNew York$81K
- Amon AsgharpourNew York$58K
- Giuseppe CullaroNew York$50K
- Julia WattacherilNew York$37K
- Gene ImNew York$15K
- Elizabeth VernaNew York$11K
- Rajani SharmaNew York$11K
- Annmarie LiapakisNew York$10K
- Alyson FoxNew York$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.